HOPE

HOPE, short for Human Organs, Physiology, and Engineering, is a $50M Wellcome Leap program aimed at building human tissues, organoids, and organs. It sits under Wellcome Leap and is already active, with Annie Moisan, PhD, directing the work from an engineering and stem-cell science background. The program brings academic institutions, foundations, and companies into the same development effort. Its two core aims are to create a multiorgan platform that can replicate human immune responses for drug testing and to advance bioengineered kidney technology for people with end-stage renal disease. The program is in execution, and no open RFP is visible. The eligibility profile allows for-profit, nonprofit, university, and research teams, while excluding individuals. HOPE is best for teams that can bridge engineering, tissue science, and translational testing. The program is not a broad open call; it is a managed cooperative-agreement effort built around selected performers. Its appeal lies in the combination of organ engineering, drug-testing relevance, and renal outcomes in a single agenda.

Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.